Q-omics provides the consensus-scored ACTL7B profile across patient tissues and cancer cell-line models. ACTL7B expression is associated with patient survival in 20 of 34 cancer types, with the highest sampling consensus in COAD. Among the 18 cancer types available for tumor–normal comparison, ACTL7B is differentially expressed in 4, with the highest sampling consensus in HNSC. Additionally, ACTL7B RNA expression shows 6,275 significant pathway-activity associations, with the highest sampling consensus in STAD. Together, these results highlight COAD, HNSC, and STAD as cancer lineages where ACTL7B shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ACTL7B — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ACTL7B survival associations across molecular data types. ACTL7B RNA expression shows survival associations in the most cancer types (20), followed by mutation status (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ACTL7B RNA expression–survival associations across cancer types. High ACTL7B expression shows unfavorable associations in COAD, CHOL, LIHC and MESO, but favorable associations in SCLC and BRCA. The COAD Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .004). Together, the overview and detailed table identify COAD as the clearest survival context for ACTL7B RNA expression.
This table summarizes ACTL7B tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 4. The strongest signals are observed in HNSC for RNA.
This table ranks reproducible tumor–normal expression differences for ACTL7B. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ACTL7B shows lower tumor expression in LUAD and THCA and higher tumor expression in HNSC and COAD. The HNSC box plot shows higher ACTL7B RNA expression in tumor versus normal tissue (log2 FC = +0.028, t-test p = .019).
This table shows molecular features associated with ACTL7B in patient tissues and cancer cell lines. In patient samples, ACTL7B shows the broadest associations at the RNA and protein expression levels, with STAD recurring as the lineage with the largest associated feature set. In cancer cell lines, ACTL7B RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BREAST, while CRISPR and shRNA rows add functional-dependency signals in BONE and LARGE_INTESTINE.
